Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology

International Journal of Molecular Sciences

Volumn 13, Issue 2, 2012, Pages 2219-2238

  Pohanka, Miroslav ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Agonist; Alzheimer's disease; Antagonist; Cholinergic anti inflammatory pathway; Cognitive disorder; Inflammation; Schizophrenia

Indexed keywords

1 (5 CHLORO 2,4 DIMETHOXYPHENYL) 3 (5 METHYLISOXAZOL 3 YL)UREA; 1 [6 (4 FLUOROPHENYL)PYRIDIN 3 YL] 3 (4 PIPERIDIN 1 YLBUTYL)UREA; 2'H SPIRO(4 AZABICYCLO[2.2.2]OCTANE 2,5' [1,3]OXAZOLIDIN) 2' ONE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 5 (6 [1 AZABICYCLO[2.2.2]OCT 3 YLOXY]PYRIDAZIN 3 YL) 1H INDOLE; 5 MORPHOLIN 4 YL PENTANOIC ACID (4 PYRIDIN 3 YL PHENYL)AMIDE; ABT 107; ALPHA BUNGAROTOXIN; ATROPINE; AZD 0328; BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR AGONIST; BUNGAROTOXIN RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; CONOTOXIN; LEONEX; MECAMYLAMINE; MEMANTINE; METHYLLYCACONITINE; N (1 AZABICYCLO[2.2.2]OCT 3 YL) 1H INDAZOLE 3 CARBOXAMIDE; N [2 (PYRIDIN 3 YLMETHYL) 1 AZABICYCLO[2.2.2]OCT 3 YL] 1 BENZOFURAN 2 CARBOXAMIDE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PNU 120596; RG 3487; SCOPOLAMINE; SEMAPIMOD; SEN 12333; SEN 34625; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; TC 5214; TC 5619; UNCLASSIFIED DRUG; WYE 103914; ACETYLCHOLINE; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANTI-INFLAMMATORY AGENTS; ASOXIME CHLORIDE; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; OXIMES; PYRIDINIUM COMPOUNDS;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ASYSTOLE; BRADYCARDIA; CHOLINERGIC TRANSMISSION; COGNITION; COGNITIVE DEFECT; CROHN DISEASE; DEMENTIA; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENDOTOXEMIA; HUMAN; INFLAMMATION; MENTAL DETERIORATION; NAUSEA; NONHUMAN; PAIN; PARANOID PSYCHOSIS; PARKINSON DISEASE; PROTEIN FUNCTION; REVIEW; SARCOIDOSIS; SCHIZOPHRENIA; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; TOXIN ANALYSIS; VENTILATOR INDUCED LUNG INJURY; AGONISTS; ANIMALS; ANTAGONISTS AND INHIBITORS; BRAIN; DRUG EFFECTS; HUMANS; METABOLISM; MOLECULAR TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; INFLAMMATION; MEMANTINE; MOLECULAR TARGETED THERAPY; OXIMES; PYRIDINIUM COMPOUNDS; SIGNAL TRANSDUCTION;

EID: 84857663983     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13022219     Document Type: Review

References (117)

1. Rand, J.B. Acetylcholine. WormBook 2007, doi:10.1895/wormbook.1.131.1. Available online: http://www.wormbook.org (accessed on 17 February 2012).
2. Loewi, O. Uberhumerole ubertragbarkeit der herznervenwirkung. I. Mitt. Pflugers Arch. 1921, 189, 239-242.
3. Wessler, I.; Kirkpatrick, C.J. Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. Br. J. Pharmacol. 2008, 154, 1558-1571.
4. Gabrielle, P.; Jeana, M.; Lorenza, E.C. Cytosolic choline acetyltransferase binds specifically to cholinergic plasma membrane of rat brain synaptosomes to generate membrane-bound enzyme. Neurochem. Res. 2003, 28, 543-549.
5. Phillis, J.W. Acetylcholine release from the central nervous system: A 50year retrospective. Crit. Rev. Neurobiol. 2005, 17, 161-217.
6. Llona, I. Synaptic like microvesicles: Do they participate in regulated exocytosis? Neurochem. Int. 1995, 27, 219-226.
7. Dun, A.R.; Rickman, C.; Duncan, R.R. The t-SNARE complex: A close up. Cell Mol. Neurobiol. 2010, 30, 1321-1326.
8. Snyder, D.A.; Kelly, M.L.; Woodbury, D.J. SNARE complex regulation by phosphorylation. Cell Biochem. Biophys. 2006, 45, 111-123.
9. Rotundo, R.L. Expression and localization of acetylcholinesterase at the neuromuscular junction. J. Neurocytol. 2003, 32, 743-766.
10. Sarter, M.; Parikh, V. Choline transporters, cholinergic transmission and cognition. Nat. Rev. Neurosci. 2005, 6, 48-56.
11. Hall, J.D.; McCroskey, L.M.; Pincomb, B.J.; Hatheway, C.L. Isolation of an organism resembling Clostridium baratii which produces type F botulinal toxon from an infant with botulism. J. Clin. Microbiol. 1985, 21, 654-655.
12. Aureli, P.; Fenicia, L.; Pasolini, B.; Gianfranceschi, M.; McCroskey, J.M.; Hatheway, C.L. Two cases of type infant botulism caused by neurotoxigenic clostridium butyricum in Italy. J. Infect. Dis. 1986, 154, 207-211.
13. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5, 898-902.
14. Singh, B.R. Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox. Res. 2006, 9, 73-92.
15. Hirota, S.A. A quick guide to muscarinic acetylcholine receptors. BioPharm. J. 2001, 5, 6-8.
16. Felder, C.C. Muscarinic acetylcholine receptors: Signal transduction through multiple effectors. FASEB J. 1995, 9, 619-625.
17. Tobin, G.; Giglio, D.; Lundgren, O. Muscarinic receptor subtypes in the alimentary track. J. Physiol. Pharmacol. 2009, 60, 3-21.
18. Berstein, G.; Blank, J.L.; Smrcka, A.; Higashijima, T.; Sternweis, P.C.; Exton, J.H.; Ross, E.M. Reconstitution of agonist-stimulated phoshpatidylinostiol 4,5-bisphosphate hydrolysis using purified m1 muscarinic receptor, Gq/11 and phospholipase C-β1. J. Biol. Chem. 1992, 267, 8081-8088.
19. Falkenburger, B.H.; Jensen, J.B.; Hille, B. Kinetics of M1 muscarinic receptor and G protein signaling to phospholipase C in living cells. J. Gen. Physiol. 2010, 135, 81-97.
20. Parker, E.M.; Kameyama, K.; Higashijima, T.; Ross, E.M. Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells. J. Biol. Chem. 1991, 266, 519-527.
21. Alfonzo, M.J.; de Becemberg, I.L.; de Villaroel, S.S.; de Herrerea, V.N.; Misle, A.J.; de Alfonzo, R.G. Two opposite signal transducting mechanisms regulate a G-protein-coupled guanylyl cyclase. Arch. Biochem. Biophys. 1998, 350, 19-25.
22. Horng, H.C.; Chen, F.C.; Ho, C.C.; Kuo, C.P.; Wu, C.T.; Wong, C.S. Bradycardia and hypotension refractory to ephedrine and atropine treatment: Severe autonomic dysfunction with abnormal heart rate variability. Acta Anaesthesiol. Taiwan 2006, 44, 109-112.
23. Bryant, S.M.; Rhee, J.W.; Thompson, T.M.; Aks, S.E. Pretreating rats with parenteral ophthalmic antimuscarinic agents decreases mortality from lethal organophosphate poisoning. Acad. Emerg. Med. 2007, 14, 370-372.
24. Nachum, Z.; Shupak, A.; Gordon, C.R. Transdermal scopolamine for prevention of motion sickness: Clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet. 2006, 45, 543-566.
25. Bridges, T.M.; Lebois, E.P.; Hopkins, C.R.; Wood, M.R.; Jones, C.K.; Conn, P.J.; Lindsley, C.W. The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect. 2010, 23, 229-240.
26. Woolley, M.L.; Carter, H.J.; Gartlon, J.E.; Watson, J.M.; Dawson, L.A. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 redceptor knockout mice. Eur. J. Pharmacol. 2009, 603, 147-149.
27. Sellin, A.K.; Shad, M.; Tamminga, C. Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr. 2008, 13, 985-996.
28. Nissen, C.; Nofzinger, E.A.; Feige, B.; Waldheim, B.; Radosa, M.P.; Riemann, D.; Berger, M. Differential effects of the muscarinic M1 receptor agonist RS-86 and the acetylcholine-esterase inhibitor donepezil on REM sleep regulation in healthy volunteers. Neuropsychopharmacology 2006, 31, 1294-1300.
29. Winterer, G. Why do patients with schizophrenia smoke. Curr. Opin. Psychiatry 2010, 23, 112-119.
30. Williams, J.M.; Gandhi, K.K. Use of caffeine and nicotine in people with schizophrenia. Curr. Drug Abuse Rev. 2008, 1, 155-161.
31. Rommelspacher, H.; Meier-Henco, M.; Smolka, M.; Kloft, C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur. J. Pharmacol. 2002, 441, 115-125.
32. Nasiripourdori, A.; Taly, V.; Grutter, T.; Taly, A. From toxins targeting ligand gated ion channels to therapeutic molecules. Toxins 2011, 3, 260-293.
33. Tracey, K.J. Physiology and immunolgy of the cholinergic antiinflammatory pathway. J. Clin. Invest. 2007, 117, 289-296.
34. Millar, N.S. A review of experimental techniques used for the heterologous expression of nicotinic acetylcholine receptors. Biochem. Pharmacol. 2009, 78, 766-776.
35. Lohmann, T.H.; Torrao, A.S.; Britto, L.R.; Lindstrom, J.; Hamassaki-Britto, D.E. A comparative non-radioactive in situ hybridization and immunohistochemical study of the distribution of alpha7 and alpha8 subunits of the nicotinic acetylcholine receptors in visual areas of the chick brain. Brain Res. 2000, 852, 463-469.
36. Unwin, N. Refined Structure of the nicotinic acetylcholine receptor at 4 A resolution. J. Mol. Biol. 2005, 346, 967-989.
37. Albuquerque, E.X.; Pereira, E.F.; Alkondon, M.; Rogers, S.W. Mammalian nicotinic acetylcholine receptors: From structure to function. Physiol. Rev. 2009, 89, 73-120.
38. Alkondon, M.; Pereira, E.F.R.; Cortes, W.S.; Maelicke, A.; Albuquerque, E.X. Choline is a selective agonist of alpha7 nicotnic acetylcholine receptors in the rat brain neurons. Eur. J. Neurosci. 1997, 9, 2734-2742.
39. Zhou, Y.; Nelson, M.E.; Kuryatov, A.; Choi, C.; Cooper, J.; Lindstrom, J. Human α4β2 acetylcholine receptors formed from linked subunits. J. Neurosci. 2003, 23, 9004-9015.
40. Yang, J.J.; Wang, Y.T.; Cheng, P.C.; Kuo, Y.J.; Huang, R.C. Cholinergic modulation of neuronal excitability in the rat suprachiasmatic nucleus. J. Neurophysiol. 2010, 103, 1397-1409.
41. Corringer, P.J.; Bertrand, S.; Galzi, J.L.; Devillers-Thiery, A.; Changeux, J.P.; Bertrand, D. Mutational analysis of the charge selectivity filter of the α7 nicotinic acetylcholine receptor. Neuron 1999, 22, 831-843.
42. Doley, R.; Kini, R.M. Protein complexes in snake venom. Cell. Mol. Life Sci. 2009, 66, 2851-2871.
43. Gurnaney, H.; Brown, A.; Litman, R.S. Malignant hyperthermia and muscular dystrophies. Anesth. Anal. 2009, 109, 1043-1048.
44. Langeron, O.; Birenbaum, A.; Amour, J. Airway management in trauma. Minerva Anestesiol. 2009, 75, 307-311.
45. Gatke, M.R.; Bundgaard, J.R.; Viby-Mogensen, J. Two novel mutations in the BChE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia. Pharmacogenet. Genomics 2007, 17, 995-999.
46. Leiser, S.C.; Bowlby, M.R.; Comery, T.A.; Dunlop, J. A cog in cognition: How the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol. Ther. 2009, 122, 302-311.
47. Soderman, A.; Mikkelsen, J.D.; West, M.J.; Christensen, D.Z.; Jensen, M.S. Activation of nicotinic α(7) acetylcholine receptor enhances long term potentation in wild type mice but not in APP (swe)/PS1ΔE9 mice. Neurosci. Lett. 2011, 487, 325-329.
48. Thomsen, M.S.; Hansen, H.H.; Timmerman, D.B.; Kikkelsen, J.D. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: From animal models to human pathophysiology. Curr. Pharm. Des. 2010, 16, 323-343.
49. Feher, A.; Juhasz, A.; Rimanoczy, A.; Csibri, E.; Kalman, J.; Janka, Z. Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia. Dement. Geriatr. Cogn. Disord. 2009, 28, 56-62.
50. Chu, L.W.; Ma, E.S.; Lam, K.K.; Chan, M.F.; Lee, D.H. Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer's disease patients. Dement. Geriatr. Cogn. Disord. 2005, 19, 106-112.
51. Tregellas, J.R.; Tanabe, J.; Rojas, D.C.; Shatti, S.; Olincy, A.; Johnson, L.; Martin, L.F.; Soti, F.; Kem, W.R.; Leonard, S. et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol. Psychiatry 2011, 69, 7-11.
52. Livingston, P.D.; Srinivasan, J.; Kew, J.N.; Dawson, L.A.; Gotti, C.; Moretti, M.; Shoaib, M.; Wonnacott, S. Alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur. J. Neurosci. 2009, 29, 539-550.
53. Martin, L.F.; Kem, W.R.; Freedman, R. Alpha-7 nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia. Psychopharmacology 2004, 174, 54-64.
54. Picciotto, M.R.; Caldarone, B.J.; Brunzell, D.H.; Zachariou, V.; Stevens, T.R.; King, S.L. Neuronal nicotinic acetylcholine receptor subunit knockout mice: Physiological and behavioral phenotypes and possible clinical inplications. Pharmacol. Ther. 2001, 92, 89-108.
55. Dziewczapolski, G.; Glogowski, C.M.; Masliah, E.; Heinemann, S.F. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2009, 29, 8805-8815.
56. Lester, H.A.; Fonck, C.; Tapper, A.R.; McKinney, S.; Damaj, M.I.; Balogh, S.; Owens, J.; Wehner, J.M.; Collins, A.C.; Labarca, C. Hypersensitive knockin mouse strains identify receptors and pathways for nicotine action. Curr. Opin. Drug Discov. Devel. 2003, 6, 633-639.
57. Tracey, K.J. The inflammatory reflex. Nature 2002, 420, 853-859.
58. Borovikova, L.V.; Ivanova, S.; Zhang, M.; Yang, H.; Botchkina, G.I.; Watkins, L.R.; Wang, H.; Abumrad, N.; Eaton, J.W.; Tracey, K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405, 458-462.
59. Tracey, K.J. Reflex control of immunity. Nat. Rev. Immunol. 2009, 9, 418-428.
60. Tracey, K.J. Fat meets the cholinergic antiinflammatory pathway. J. Exp. Med. 2005, 202, 1071-1021.
61. Casserly, B.; Baram, M.; Walsh, P.; Sucov, A.; Ward, N.S. Levy, M.M. Implementing a collaborative protocol in a sepsis intervention program: Lessons learned. Lung 2011, 189, 11-19.
62. Babaev, V.R.; Patel, M.B.; Semenkovich, C.F.; Fazio, S.; Linton, M.F. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J. Biol. Chem. 2000, 275, 26293-26299.
63. Herbein, G.; Gras, G.; Khan, K.A.; Abbas, W. Macrophage signaling in HIV-1 infection. Retrovirology 2010, 7, 34:1-34:13.
64. Pohanka, M.; Snopkova, S.; Havlickova, K.; Bostik, P.; Sinkorova, Z.; Fusek, J.; Kuca, K.; Pikula, J. Macrophage-assisted inflammation and pharmacological regulation of the cholinergic anti-inflammatory pathway. Curr. Med. Chem. 2011, 18, 539-551.
65. Parrish, W.R.; Gallowitsch-Puerta, M.; Czura, C.J.; Tracey, K.J. Experimental therapeutic strategies for severe sepsis: Mediators and mechanisms. Ann. N. Y. Acad. Sci. 2008, 1144, 210-236.
66. Xiong, J.; Xue, F.S.; Yuan, Y.J.; Wang, Q.; Liao, X.; Wang, W.L. Cholinergic anti-inflammatory pathway: A possible approach to protect against myocardial ischemia reperfusion injury. Chin. Med. J. (Engl.) 2010, 123, 2720-2726.
67. Zhou, Y.; Zuo, X.; Li, Y.; Wang, Y.; Zhao, H.; Xiao, X. Nicotine inhibits tumor necrosis factor-alpha induced IL-6 and IL-8 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Rheumatol. Int. 2012, 32, 97-104.
68. Azam, L.; Mcintosh, J.M. Alpha-conotoxins as pharmacological probes of nicotinic acetylholine receptors. Acta Pharmacol. Sin. 2009, 30, 771-783.
69. Millard, E.L.; Daly, N.L.; Craik, D.J. Structure-activity relationships of alpha-conotoxins targeting neuronal nicotinic acetylcholine receptors. Eur. J. Biochem. 2004, 271, 2320-2326.
70. Favreau, P.; Krimm, I.; Le Gall, F.; Bobenrieth, M.J.; Lamthanh, H.; Bouet, F.; Servent, D.; Molgo, J.; Menez, A.; Letouneux, Y. et al. Biochemical characterization and nuclear magnetic resonance structure of novel alpha-conotoxins isolated from the venom of conus consors. Biochemistry 1999, 38, 6317-6326.
71. Hogg, R.C.; Miranda, L.P.; Craik, D.J.; Lewis, R.J.; Alewood, P.F.; Adams, D.J. Single amino acid substitutions in alpha-conotoxin PnIA shift selectivity for subtypes of the mammalian neuronal nicotinic acetylcholine receptor. J. Biol. Chem. 1999, 274, 36559-36564.
72. Dutertre, S.; Nicke, A.; Lewis, R.J. Beta2 subunit contribution to 4/7 alpha-conotoxin binding to the nicotinic acetylchline receptor. J. Biol. Chem. 2005, 280, 30460-30468.
73. Blanchfield, J.T.; Gallagher, O.P.; Cros, C.; Lewis, R.J.; Alewood, P.F.; Toth, I. Oral absorption and in vivo biodistribution of alpha-conotoxin MII and a lipidic analogue. Biochem. Biophys. Res. Commun. 2007, 361, 97-102.
74. Whiteaker, P.; Mcintosh, J.M.; Luo, S.; Collins, A.C.; Marks, M.J. 125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. Mol. Pharmacol. 2000, 57, 913-925.
75. Arias, H.R. Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. Neurochem. Int. 2000, 36, 595-645.
76. McCann, C.M.; Bracamontes, J.; Steinbach, J.H.; Sanes, J.R. The cholinergic antagonist alpha-bungarotoxin also binds and blocks a subset of GABA receptors. Proc. Natl. Acad. Sci. USA 2006, 103, 5149-5154.
77. Chang, C.C. Looking back on the discovery of alpha-bungarotoxin. J. Biomed. Sci. 1999, 6, 368-375.
78. Hawgood, B.J. Professor Chen-Yuan Lee, MD (1915-2001), pharmacologist: Snake venom research at the Institute of Pharmacology, National Taiwan University. Toxicon 2002, 40, 1065-1072.
79. Chu, N.S. Contribution of a snake venom toxin to myasthenia gravis: The discovery of alpha-bungarotoxin in Taiwan. J. Hist. Neurosci. 2005, 14, 138-148.
80. Aracava, Y.; Pereira, E.F.; Maelicke, A.; Albuquerque, E.X. Memantine blocks alpha7* nicotnic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 2005, 312, 1195-1205.
81. Banerjee, P.; Samoriski, G.; Gupta, S. Comments on "Memantine blocks alpha7* nicotnic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons". J. Pharmacol. Exp. Ther. 2005, 313, 928-929.
82. Taly, A.; Corringer, P.J.; Guedin, D.; Lestage, P.; Changeux, J.P. Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov. 2009, 8, 733-750.
83. Santos, M.D.; Alkondon, M.; Pereira, E.F.; Aracava, Y.; Eisenberg, H.M.; Maelicke, A.; Albuquerque, E.X. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol. Pharmacol. 2002, 61, 1222-1234.
84. Schedel, A.; Thornton, S.; Schloss, P.; Kluter, H.; Bugert, P. Human platelets express functional alpha 7-nicotinic acetylcholine receptors. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 928-934.
85. Kassa, J. Review of oximes in the antidotal treatment of poisoning by organophoshorus nerve agents. J. Toxicol. Clin. Toxicol. 2002, 40, 803-816.
86. Pohanka, M.; Jun, D.; Kuca, K. Amperometric biosensor for evaluation of competitive cholinesterase inhibition by the reactivation HI-6. Anal. Lett. 2007, 40, 2351-2359.
87. Soukup, O.; Pohanka, M.; Tobin, G.; Jun, D.; Fusek, J.; Musilek, K.; Marek, J.; Kassa, J.; Kuca, K. The effect of HI-6 on cholinesterases and on the cholinergic system of the rat bladder. Neuroendocrinol. Lett. 2008, 29, 759-762.
88. Pohanka, M.; Pavlis, O.; Pikula, J.; Treml, F.; Kuca, K. Modulation of tularemia disease progress by the bisquaternary pyridinium oxime HI-6. Acta Vet. (Brno) 2010, 79, 443-448.
89. Pohanka, M.; Pejchal, J.; Horackova, S.; Kuca, K.; Bandouchova, H.; Damkova, V.; Pikula, J. Modulation of ionising radiation generated oxidative stress by HI-6 (asoxime) in a laboratory rat model. Neuroendocrinol. Lett. 2010, 31, 62-68.
90. Tsuji, A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport system. NeuroRx 2005, 2, 54-62.
91. Liu, X.; Testa, B.; Fahr, A. Lipophilicity and its relationship with passive drug permeation. Pharm. Res. 2011, 28, 962-977.
92. Ohtsuki, S.; Terasaki, T. Contribution of carrier-mediated transport system to the blood-brain barrier as a supporting and protecting interface for the brain, importance for CNS drug discovery and development. Pharm. Res. 2007, 24, 1745-1758.
93. Wallace, T.L.; Callahan, P.M.; Tehim, A.; Bertrand, D.; Tombaugh, G.; Wang, S.; Xie, W.; Rowe, W.B.; Ong, V.; Graham, E. et al. RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 2011, 336, 242-253.
94. Chiron, C.; Haydar, S.N.; Aschmies, S.; Bothmann, H.; Castaldo, C.; Cocconcelli, G.; Comery, T.A.; Di, L.; Dunlop, J.; Lock, T. et al. Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: Identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914). J. Med. Chem. 2010, 53, 4379-7389.
95. Roncarati, R.; Scali, C.; Comery, T.A.; Grauer, S.M.; Aschmi, S.; Bothmann, H.; Jow, B.; Kowal, D.; Gianfriddo, M.; Kelley, C. et al. Procognitive and neuroprotective activity of novel alpha 7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J. Pharmacol. Exp. Ther. 2009, 329, 459-468.
96. Malysz, J.; Anderson, D.J.; Gronlien, J.H.; Ji, J.; Bunnelle, W.H.; Hakerud, M.; Thorin-Hagene, K.; Ween, H.; Helfrich, R.; Hu, M. et al. In vitro phramacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J. Pharmacol. Exp. Ther. 2010, 334, 863-874.
97. Asenjo Lobos, C.; Komossa, K.; Rummel-Kluge, C.; Hunger, H.; Schmid, F.; Schwarz, S.; Leucht, S. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2010, 83, doi:10.1002/14651858.CD006633.
98. Bertrand, D.; Gopalakrishnan, M. Allosteric modulation of nicotinic acetlycholine receptors. Biochem. Pharmacol. 2007, 74, 1155-1163.
99. Kalappa, B.I.; Gusev, A.G.; Uteshev, V.V. Activation of functional α7-containing nAChRs in hippocampal CA1 pyrmidal neurons by physiologica levels of choline in the presence of PNU-120596. PLoS One 2010, 5, doi:10.1371/journal.pone.0013964.
100. Lippiello, P.M.; Beaver, J.S.; Gatto, G.J.; James, J.W.; Jordan, K.G.; Traina, V.M.; Xie, J.; Benchrif, M. TC-5214 (S-(+)-mecamylamine): A neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci. Ther. 2008, 14, 266-277.
101. Sydserff, S.; Sutton, E.J.; Song, D.; Quirk, M.C.; Maciag, C.; Li, C.; Jonak, G.; Gurley, D.; Gordon, J.C.; Christian, E.P. et al. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem. Pharmacol. 2009, 78, 880-888.
102. Hauser, T.A.; Kucinski, A.; Jordan, K.G.; Gatto, G.J.; Wersinger, S.R.; Hesse, R.A.; Stachowiak, E.K.; Stachowiak, M.K.; Papke, R.L.; Lippiello, P.M. et al. TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol. 2009, 78, 803-812.
103. Jonnala, R.R.; Grahama, J.H.; Terry, A.V.; Beach, J.W.; Young, J.A.; Buccafusco, J.J. Relative level of cytoprotection produced by analogs of choline and the role of alpha 7-nicotinic acetylcholine receptors. Synapse 2003, 47, 262-269.
104. Pohanka, M. Cholinesterases, a target of pharmacology and toxicology. Biomed. Pap. Olomouc 2011, 155, 219-223.
105. Minutoli, L.; Squadrito, F.; Nicotina, P.A.; Giuliani, D.; Ottani, A.; Polito, F.; Bitto, A.; Irrera, N.; Guzzo, G.; Spaccapelo, L. et al. Melanocortin 4 receptor stimulation decreases pancreatitis severity in rats by activation of the cholinergic anti-inflammatory pathway. Crit. Care Med. 2011, 39, 1089-1096.
106. Rosas-Ballina, M.; Tracey, K.J. Cholinergic control of inflammation. J. Intern. Med. 2009, 265, 663-679.
107. Rosas-Ballina, M.; Goldstein, R.S.; Gallowitsch-Puerta, M.; Yang, L.; Valdes-Ferrer, S.I.; Patel, N.B.; Chavan, S.; Al-Abed, Y.; Yang, H.; Tracey, K.J. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol. Med. 2009, 15, 195-202.
108. Pavlov, V.A.; Ochani, M.; Yang, L.H.; Gallowitsch-Puerta, M.; Ochani, K.; Lin, X.; Levi, J.; Parrish, W.R.; Rosas-Ballina, M.; Czura, C.J. et al. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit. Care Med. 2007, 35, 1139-1144.
109. Kox, M.; Pompe, J.C.; Peters, E.; VAneker, M.; van der Laak, J.W.; van der Hoeven, J.G.; Scheffer, G.J.; Hoedemaekers, C.W.; Pickkers, P. α7 nicotinic acetylcholine receptor agonist GTS-21 attenuates ventilator-induced tumour necrosis factor-α production and lung injury. Br. J. Anaesth. 2011, 107, 559-566.
110. Tregellas, J.R.; Tanabe, J.; Rojas, D.C.; Shatti, S.; Olincy, A.; Johnson, L.; Martin, L.F.; Soti, F.; Kem, W.R.; Leonard, S.; Freedman, R. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol. Psychiatry 2011, 69, 7-11.
111. Bowman, G.; Bonneau, R.H.; Chinchilli, V.M.; Tracey, K.J.; Cockroft, K.M. A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm. Neurocit. Care 2006, 5, 222-229.
112. Oke, S.L.; Tracey, K.J. From CNI-1493 to the immunological homunculus: Physiology of the inflammatory reflex. J. Leukoc. Biol. 2008, 83, 512-517.
113. Bacher, M.; Dodel, R.; Aljabari, B.; Keyvani, K.; Marambaud, P.; Kayed, R.; Glabe, C.; Goertz, N.; Hoppmann, A.; Sachser, N. et al. CNI-1493 inhibits Abeta production, and cognitive deterioration in an animal model of Alzheimer's disease. J. Exp. Med. 2008, 205, 1593-1599.
114. Oettinger, C.W.; D'Souza, M.J. Synergism in survival to endotoxic shock in rats given microencapsulated CNI-1493 and antisense oligomers to NF-kappaB. J. Microencapsul. 2010, 27, 372-376.
115. Dotan, I.; RAchmilewitz, D.; Schreiber, S.; Eliakim, R.; van der Woude, C.J.; Kornbluth, A.; Buchman, A.L.; Bar-Meir, S.; Bokemeyer, B.; Goldin, E. et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 2010, 59, 760-766.
116. The, F.O.; Boeckxstaens, G.E.; Snoek, S.A.; Cash, J.L.; Bennink, R.; Larosa, G.J.; van den Wijngaard, R.M.; Greaves, D.R.; de Jonge, W.J. Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology 2007, 133, 1219-1228.
117. Van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology 2004, 172, 375-383.